Trial Profile
Phase II study of implantation of carmustine wafers, followed by radiation therapy and concomitant temozolomide and bevacizumab for newly diagnosed glioblastoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms RADICAL TRIAL
- 05 May 2018 Planned End Date changed from 14 Dec 2020 to 31 Oct 2020.
- 05 May 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2017 Planned number of patients changed from 55 to 47.